Search - tctmd.com

Displaying 21 - 40 of 96

Sort: Relevancy | Date

News Daily News

Upstream Care Lacking for Many CTO PCI Patients in VA Health System

Yael L. Maxwell

February 08, 2023

News Conference News AHA 2022

Etripamil Nasal Spray in Paroxysmal SVT Speeds Conversion to Sinus Rhythm: RAPID

Shelley Wood

November 07, 2022

News Conference News AHA 2022

Big Drops in Blood Pressure With Baxdrostat: BrigHTN Phase II Study

Michael O'Riordan

November 07, 2022

News Daily News

Extreme BP-Lowering Harmful After Stroke Thrombectomy: ENCHANTED2/MT

Todd Neale

November 01, 2022

News Daily News

RAPID: Positive Top-line Results for Etripamil Nasal Spray in Paroxysmal SVT

Todd Neale

October 17, 2022

Presentation TCT 2022

TCT 548: Impact of Cardiovascular Diseases, Calcium Channel Blockers, and Beta-Blockers on Two-Year Mortality of Patients with COVID-19: A Single-Center Retrospective Analysis

Presenter: Rashid Alhusain

September 18, 2022

News Daily News

Certain CV Meds Tied to Higher MI Risk in Warmer Weather

Caitlin E. Cox

August 04, 2022

News Conference News ESC Heart Failure 2022

Aficamten Safe, Effective for Up to 6 Months in Obstructive HCM: REDWOOD-HCM OLE

Todd Neale

May 31, 2022

News Daily News

FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy

Michael O'Riordan

April 29, 2022

News Conference News ACC 2022

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

Shelley Wood

April 03, 2022

News Conference News ACC 2022

In ANOCA, Diltiazem Fails to Improve Vasomotor Function: EDIT-CMD

Caitlin E. Cox

April 02, 2022

News Conference News ACC 2022

Mavacamten Slashes Need for Septal Reduction in Obstructive HCM: VALOR-HCM

Yael L. Maxwell

April 02, 2022

News Daily News

Statin Intolerance Overestimated—Only ‘Small Number’ Get Side Effects: Meta-analysis

Michael O'Riordan

February 18, 2022

News Daily News

Vasospasm Linked to Higher Atherosclerotic Risk in Patients With ANOCA

Yael L. Maxwell

January 27, 2022

News Daily News

Optimal Medical Therapy for Stable Angina: Which Drugs? How Long?

Michael O'Riordan

January 25, 2022

News Conference News HRS 2021

Spinal Cord Stimulation Reduces Post-CABG AF: Pilot Study

Michael O'Riordan

July 30, 2021

News Conference News ACC 2021

‘Enormous’ QoL Improvements With Mavacamten in HCM

Shelley Wood

May 15, 2021

News Daily News

Skin Cancer Risk With Common Diuretics Confirmed Anew

L.A. McKeown

April 14, 2021

News Daily News

ACE Inhibitors, ARBs: Still No Link to COVID-19 Risks, New Analyses Show

Michael O'Riordan

December 21, 2020

News Conference News ESC 2020

Insights From a Deep Dive Into CV Risk Among Hospitalized COVID-19 Patients

Shelley Wood

September 04, 2020

Advertisement

Upstream Care Lacking for Many CTO PCI Patients in VA Health System

Etripamil Nasal Spray in Paroxysmal SVT Speeds Conversion to Sinus Rhythm: RAPID

Big Drops in Blood Pressure With Baxdrostat: BrigHTN Phase II Study

Extreme BP-Lowering Harmful After Stroke Thrombectomy: ENCHANTED2/MT

RAPID: Positive Top-line Results for Etripamil Nasal Spray in Paroxysmal SVT

TCT 548: Impact of Cardiovascular Diseases, Calcium Channel Blockers, and Beta-Blockers on Two-Year Mortality of Patients with COVID-19: A Single-Center Retrospective Analysis

Certain CV Meds Tied to Higher MI Risk in Warmer Weather

Aficamten Safe, Effective for Up to 6 Months in Obstructive HCM: REDWOOD-HCM OLE

FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

In ANOCA, Diltiazem Fails to Improve Vasomotor Function: EDIT-CMD

Mavacamten Slashes Need for Septal Reduction in Obstructive HCM: VALOR-HCM

Statin Intolerance Overestimated—Only ‘Small Number’ Get Side Effects: Meta-analysis

Vasospasm Linked to Higher Atherosclerotic Risk in Patients With ANOCA

Optimal Medical Therapy for Stable Angina: Which Drugs? How Long?

Spinal Cord Stimulation Reduces Post-CABG AF: Pilot Study

‘Enormous’ QoL Improvements With Mavacamten in HCM

Skin Cancer Risk With Common Diuretics Confirmed Anew

ACE Inhibitors, ARBs: Still No Link to COVID-19 Risks, New Analyses Show

Insights From a Deep Dive Into CV Risk Among Hospitalized COVID-19 Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content